Incidence of hepatitis C virus infection among people living with HIV: An Egyptian cohort study

Elrashdy, Fatma; Hagag, Suzan; Mohamed, Rahma; Alem, Shereen Abdel; Meshaal, Safa; Cordie, Ahmed; Elsharkawy, Aisha; Esmat, Gamal

doi:10.4102/sajhivmed.v23i1.1442

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Egypt used to have the highest HCV infection rate. Two probability-based studies conducted in 2008 and 2015 suggested a decline in HCV antibody prevalence from 14.7% to 10%, respectively [3,[5][6][7]. The most recent prevalence data were gathered from Egypt's national initiative for HCV screening and treatment.…”

Section: Global and Egypt Prevalence Of Hcvmentioning

confidence: 99%

Future Prospects, Approaches, and the Government’s Role in the Development of a Hepatitis C Virus Vaccine

Tabll,

Sohrab,

Ali

et al. 2023

Pathogens

View full text Add to dashboard Cite

Developing a safe and effective vaccine against the hepatitis C virus (HCV) remains a top priority for global health. Despite recent advances in antiviral therapies, the high cost and limited accessibility of these treatments impede their widespread application, particularly in resource-limited settings. Therefore, the development of the HCV vaccine remains a necessity. This review article analyzes the current technologies, future prospects, strategies, HCV genomic targets, and the governmental role in HCV vaccine development. We discuss the current epidemiological landscape of HCV infection and the potential of HCV structural and non-structural protein antigens as vaccine targets. In addition, the involvement of government agencies and policymakers in supporting and facilitating the development of HCV vaccines is emphasized. We explore how vaccine development regulatory channels and frameworks affect research goals, funding, and public health policy. The significance of international and public-private partnerships in accelerating the development of an HCV vaccine is examined. Finally, the future directions for developing an HCV vaccine are discussed. In conclusion, the review highlights the urgent need for a preventive vaccine to fight the global HCV disease and the significance of collaborative efforts between scientists, politicians, and public health organizations to reach this important public health goal.

show abstract

Section: Global and Egypt Prevalence Of Hcvmentioning

confidence: 99%

Future Prospects, Approaches, and the Government’s Role in the Development of a Hepatitis C Virus Vaccine

Tabll,

Sohrab,

Ali

et al. 2023

Pathogens

View full text Add to dashboard Cite

show abstract

Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis

Artenie¹,

Stone²,

Fraser³

et al. 2023

The Lancet Gastroenterology & Hepatology

View full text Add to dashboard Cite

Prevalence of Hepatitis C Virus Infection among People Living with HIV/AIDS Attending Specialist Hospital Sokoto, Nigeria

Iduh, M. U.,

Enitan, S. S.,

Umar, A. I.

et al. 2024

UJMR

View full text Add to dashboard Cite

Study’s Novelty/Excerpt This study assesses HIV/HCV coinfection and associated risk factors among patients at Specialist Hospital, Sokoto, highlighting the seroprevalence of HCV among HIV/AIDS reactive individuals. The novelty lies in its detailed demographic analysis, revealing significant age, gender, tribal, educational, and occupational disparities, with a notably high seropositivity among people who inject drugs. These findings underscore the necessity for targeted HCV screening and intervention strategies in HIV/AIDS patients, particularly in demographic subgroups identified as having higher seroprevalence, to improve early diagnosis and management. Full Abstract The Hepatitis C virus (HCV) remains a large healthcare burden. Human Immunodeficiency Virus (HIV) and HCV coinfection are major global health concerns worldwide. This study aimed to assess the HIV/HCV coinfection and the potential risk factors among people attending Specialist Hospital, Sokoto. A cross-sectional seroprevalence survey of HCV infection was carried out on 77 HIV/AIDS reactive subjects attending Specialist Hospital, Sokoto, from 30th March 2021 to 4th May 2021. Serum samples were tested for anti-HCV antibodies using immunochromatographic test. Of the 77 study participants, the overall anti-HCV antibody prevalence was 5.2%. The 36-40 age group revealed the highest seropositivity of 18.18%, followed by 51-55 years (14.29%) and the least (11.11%) among 26-30 years. Females had the highest seropositivity of 6.25% and males least (3.45%). The highest seropositivity was seen among the Hausa tribe (7.14%), while the least in Fulani (5.56%). The highest seropositivity was recorded among people with no formal education (6.82%), while people with formal education had the least (5.88%). The highest seropositivity was seen in self-employed individuals (6.52%) regarding occupational status, while employed individuals had the least (4.17%). Married individuals had the highest seropositivity of 7.69%, while the divorced and widow/widower had 5.26% and 4.76% respectively. People who injected drugs recorded the highest seropositivity of 33.33%, with multiple sex partners at 6.90%, while people who shared sharp objects had the least (6.67%). There were no significant differences statistically in HCV seroprevalence among the different age categories, gender, tribe, education, occupation, marital and risk factors (p>0.05). The HCV prevalence rate (5.8%) observed in this study underscored the need to intensify HCV screening among people living with HIV/AIDS for early diagnosis and management of cases.

show abstract

Incidence of hepatitis C virus infection among people living with HIV: An Egyptian cohort study

Cited by 3 publications

References 21 publications

Future Prospects, Approaches, and the Government’s Role in the Development of a Hepatitis C Virus Vaccine

Future Prospects, Approaches, and the Government’s Role in the Development of a Hepatitis C Virus Vaccine

Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis

Prevalence of Hepatitis C Virus Infection among People Living with HIV/AIDS Attending Specialist Hospital Sokoto, Nigeria

Contact Info

Product

Resources

About